ClinicalIntelPulse · Clinical Disease Landscape Lite

import { wrapFetchWithPayment } from "@x402/fetch";
import { privateKeyToAccount } from "viem/accounts";

const account = privateKeyToAccount(process.env.PRIVATE_KEY);
const fetchWithPay = wrapFetchWithPayment(fetch, account);

const res = await fetchWithPay("https://clinicalintelpulse.theaslangroupllc.com/api/clinical/disease-landscape-lite", {
  method: "GET",
});
const data = await res.json();

curl -X GET \
  "https://clinicalintelpulse.theaslangroupllc.com/api/clinical/disease-landscape-lite?condition=Disease+area+%E2%80%94+e.g.+%22Parkinson+Disease%22+%7C+%22Breast+Cancer%22+%7C+%22NASH%22+%7C+%22Heart+Failure%22+%7C+%22Schizophrenia%22" \
  -H "X-PAYMENT: <signed x402 payment>"

{
  "deterministic": true,
  "pipeline_overview": {
    "completed_total": 210,
    "phase2_count": 48,
    "phase3_count": 19,
    "total_active": 67
  },
  "query_summary": {
    "as_of": "2026-07-25",
    "condition": "NASH (Nonalcoholic Steatohepatitis)"
  },
  "sample_phase3_trials": [
    {
      "nctId": "NCT04858633",
      "sponsor": "Novo Nordisk A/S",
      "status": "ACTIVE_NOT_RECRUITING",
      "title": "Semaglutide in NASH"
    }
  ],
  "status_breakdown": {
    "ACTIVE_NOT_RECRUITING": 22,
    "COMPLETED": 14,
    "RECRUITING": 31
  },
  "top_countries": [
    {
      "country": "United States",
      "trial_count": 40
    }
  ],
  "top_sponsors": [
    {
      "sponsor": "Novo Nordisk A/S",
      "sponsor_class": "INDUSTRY",
      "trial_count": 6
    }
  ],
  "upsell": {
    "adds": "Approved drugs, mechanism-of-action landscape (crowded/emerging/gaps), PDUFA calendar, M&A deal activity, investment thesis, 0-100 opportunity score.",
    "full_product": "/api/clinical/disease-landscape",
    "price_usd": 0.35
  }
}